Oncobesity News Posts
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
2025.06.02 10:36 Novo Nordisk’s semaglutide product. Photo: Handout Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as
“I’m Thin, And I’m Yellow”: Doctors Sound Alarm On Concerning New Ozempic Side Effect
The “miracle weight-loss drug” Ozempic, once hailed as a shortcut to shedding pounds without the hard work, is now at the center of an alarming
The Ozempic Era and Shifting Obesity Blame
Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41,
Is Obesity Genetic or Environmental? YES!
Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific
Predicting and Preventing Alzheimer’s Disease
This week I published an essay in the journal Science on the exciting potential to get ahead of Alzheimer’s disease. That was written a few
How do GLP-1 drugs work? This book answers all your questions
Dr Alexandra Sowa, author of ‘The Ozempic Revolution’, talks about how GLP-1s are changing the way America eats, dresses and shops.
How Making GLP-1s Available Over the Counter Can Unlock Their Full Potential
When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type
GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Abstract Aims To assess if there is a difference in the oncogenic risk between GLP-1 RA and comparators in randomized controlled trials. Materials and Methods
Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies
Four leading organizations in lifestyle medicine, obesity medicine, and nutrition-the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine
Food and fitness make or break success on weight loss meds, report finds – ABC News
Food and fitness make or break success on weight loss meds, report finds ABC News Medical groups release guidance on nutritional support for patients using GLP-1s Healio
Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Science Advances, Volume 11, Issue 22, May 2025.
FDA Accepts Application for Oral Version of Wegovy
The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like
For diabetics, weight-loss drugs might lessen cancer risk, study finds
Excess body weight can raise the risk of certain cancers. So researchers have been wondering: Might blockbuster weight-loss drugs like Wegovy, Ozempic and Zepbound also
GLP-1 RAs: Psychiatric, Cognitive, and Quality of Life Effects
This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of
8 GLP-1 updates
Over the past month, studies have shown Zepbound leads to more weight loss than Wegovy, and GLP-1 drugs may lower obesity-related cancer risk better than
Chutes & Ladders—20-year Novo vet lands first CEO role
In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics has hired a former GLP-1 leader to
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best–known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.Read more…
AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare
ANN ARBOR, Mich.–(BUSINESS WIRE)–AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically
Could protein bars be the next GLP-1?
Could collagen prove a side effect-free alternative to weight-loss drugs like GLP-1?
Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide
In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, constitutes a national security threat to the U.S.
Novo Nordisk Partners with Telehealth for Wegovy Promotion
May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the
Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis
submitted by /u/PlayfulReputation112 [link] [comments]
Massive Study Of 215,000+ Ozempic Users Reveal Incredible Benefits Beyond Weight Loss
Shutterstock Few drugs in history have gone from initial approval to being a household name faster than the various GLP-1 drugs, including Ozempic and Wegovy.
The most bizarre side effects of GLP-1 weight loss drugs, from ‘Ozempic feet’ to cavities to a runny nose
“We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.
Is Ozempic ruining your teeth? What to know about impact on dental health
Despite their widely touted benefits — primarily weight loss and diabetes control, among others — GLP-1 medications have also been linked to some unwelcome side
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death
For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4
GLP-1 prescriptions for weight loss are shooting up, despite obstacles
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a new Fair Health report.
Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight
Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally safe when added to Wegovy: In the Phase 2b QUALITY trial, patients who were
GLP-1 prescriptions for weight loss soar, despite obstacles
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.
Cysteine Deficiency Drives Weight Loss by Depleting CoA
This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised
Blue Cross Blue Shield plans reverse course on GLP-1 coverage
Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the highly popular medications.
Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery, Published online: 28 May 2025; doi:10.1038/s41573-025-01231-3 Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Weight-loss drugs may lower risk of obesity-related cancers
Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers
By Dennis Thompson HealthDay ReporterWEDNESDAY, May 28, 2025 (HealthDay News) — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help…
Novo Nordisk’s 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry’s hottest opportunity in recent memory.
Can GLP-1s Protect Against Obesity-Related Cancers?
GLP-1 receptor agonists may modestly reduce the risk for 14 obesity-related cancers, especially colorectal cancer, among adults with obesity and diabetes, new data suggest. Medscape
Patenting Privation (Part III): Empowering Revenge
Just over a year ago on these pages, I continued our look at the patent franchises protecting the defining drugs of our time, Novo Nordisk